Host: Jennifer Caudle, DO <br>

Guest: Deepa Rangachari, MD <br>


  <p>Survival rates for patients with non-small cell lung cancer have notably improved thanks to the development of targeted therapies and immunotherapies. With these recent advancements on the forefront, Dr. Deepa Rangachari joins Dr. Jennifer Caudle to discuss the KEYNOTE-189 study and how it could change our approach to treating patients with non-small cell lung cancer.</p>

The Importance of Symptom Management for NSCLC Patients

Not only is lung cancer the leading cause of cancer deaths among females and males, but it’s also the most common type of cancer. Despite its high prevalence and mortality rates, communicative care between non-small cell lung cancer (NSCLC) patients and their providers is still unfortunately lacking.
In an effort to both address and resolve this disparity, Closing the Gaps in NSCLC will focus on the latest guidelines and the current therapeutic landscape within NSCLC.
This non-certified educational series is sponsored by Lilly. Content for this series is produced and controlled by ReachMD. This series is intended for healthcare professionals only.
 Sponsored by